What is apathy in Parkinson’s?
Apathy is defined as a persistent reduction in a person’s motivation and capacity to initiate goal-directed behavior. In Parkinson’s disease, not only motor symptoms, but also non-motor manifestations such as apathy, depression, cognitive impairment, sleep problems, and autonomic symptoms significantly affect quality of life.
Apathy is not the same as depression
The two conditions can co-occur, but they are not the same clinical picture. While depressed mood, guilt, hopelessness, and loss of pleasure may be prominent in depression, the core issue in apathy is a reduction in the “drive to initiate” and goal-directed behavior. A person may experience difficulty initiating daily activities without being noticeably sad and while physically capable of doing them.
Why is there a significant treatment gap?
Ariadne Bio and previous systematic reviews note that clinically meaningful apathy can be seen in a significant proportion of Parkinson’s patients. Despite this, there is no medication specifically approved for Parkinson’s apathy. Dopaminergic therapies can improve motor symptoms, but apathy is not necessarily expected to improve to the same extent.
What kind of molecule is AB-300?
According to the company’s statement, AB-300 is an oral, investigational small molecule and a partial agonist at the 5-HT2A receptor. It is reported not to show measurable activity at dopamine receptors or the dopamine transporter in off-target screens. The development objective is to create an adjunctive treatment option for apathy that persists despite stable dopaminergic therapy.
What does the term “psychedelic-like” mean?
A significant portion of classic psychedelic compounds activate the 5-HT2A receptor. However, “targeting the same receptor” does not necessarily produce the same subjective experience. AB-300 is described by the company as a 5-HT2A partial agonist designed for a non-hallucinogenic profile. This characteristic cannot be considered definitive until confirmed by safety and pharmacodynamic data in human studies.
What did the preclinical data show?
The company reported preclinical results indicating that AB-300 increased effort-based motivated behavior in a tetrabenazine-based model of motivational deficit used to model dopamine depletion. Such animal or experimental models are valuable in terms of mechanism and dose selection; however, they do not prove that it will improve clinical apathy in humans.
What is the goal of the Phase 1b program?
According to the plan published by Ariadne Bio, Phase 1b will proceed in stages. The first part aims to characterize safety and pharmacokinetics in humans, the subsequent part aims for appropriate dose selection in Parkinson’s patients, and the controlled 28-day part aims to seek a treatment signal and functional validation regarding apathy. The company reports that as of September 2026, the program is funded and the first-in-human study is expected to begin in the second half of 2026.
What do we not know yet?
The safe dose in humans, the true hallucinogenic effect profile, interactions with Parkinson’s medications, cognitive effects, blood pressure or cardiovascular effects, and most importantly, clinical efficacy have not yet been demonstrated. Furthermore, due to the heterogeneity of apathy, it is unknown which patient subgroup would benefit from a potential treatment.
How is apathy measured?
In clinical studies, apathy is not evaluated solely by the patient saying “I lack motivation.” Validated apathy scales, measures of goal-directed behavior, functionality, and caregiver observations can be used together. Phenotyping is important because motor impairment, depression, and cognitive impairment can mimic the presentation of apathy in Parkinson’s.
Why is this approach scientifically interesting?
If the program is successful, it could demonstrate that receptor pharmacology emerging from psychedelic research can be translated into non-hallucinogenic molecules that can be used chronically at home, rather than intensively supervised single-session treatments. However, this is currently a development hypothesis. The premise of “the same benefit without the psychedelic effect” can only be tested with controlled human data.
Our approach at our Bodrum clinic
When evaluating apathy in Parkinson’s, comorbid causes such as depression, cognitive impairment, sleep problems, medication side effects, hypotension, pain, and motor impairment must first be differentiated. AB-300 is not currently in routine clinical use and is not an approved treatment. It is necessary to monitor new molecules by distinguishing between a promising mechanism and proven clinical efficacy.
References
- STAT, September 17, 2026: News on the development of a psychedelic-like drug for Parkinson’s apathy
- Ariadne Bio: AB-300 program, mechanism, and Phase 1b plan
- den Brok MGHE et al. Apathy in Parkinson’s disease: systematic review and meta-analysis. Movement Disorders. 2015.
- Cunningham MJ et al. Pharmacology of non-hallucinogenic 5-HT2A agonists. ACS Chemical Neuroscience. 2023.
Last medical review: September 18, 2026
